Patents by Inventor Mehran Khodadoust
Mehran Khodadoust has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20110076278Abstract: Methods for treatment of ocular disorders using steroids modulate the effects of local and systemic hypoxic events mediated by hypoxia inducible factor-1 (HIF-1). Steroids that are useful as HIF-1 modulators include bufalin, digitoxigenin, digoxin, lanatoside C, strophantin K, uzarigenin, ouabain and proscillaridin. In some embodiments the ocular disorder is characterized by ischmia.Type: ApplicationFiled: August 1, 2006Publication date: March 31, 2011Inventor: Mehran Khodadoust
-
Publication number: 20090136959Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: October 23, 2008Publication date: May 28, 2009Inventors: Sean A. McCarthy, Christopher C. Fraser, John D. Sharp, Thomas M. Barnes, Susan J. Kirst, Paul S. Myers, Nicholas Wrighton, Andrew D.J. Goodearl, Douglas A. Holtzman, Mehran Khodadoust
-
Publication number: 20090023666Abstract: The invention features compounds of formulas I or II: and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds.Type: ApplicationFiled: January 9, 2007Publication date: January 22, 2009Inventors: Gregory Gardiner, Mehran Khodadoust, Hans-Jurgen Hess, Saijat Hussoin, Reimar Bruening
-
Publication number: 20080027010Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadienolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.Type: ApplicationFiled: January 12, 2007Publication date: January 31, 2008Inventors: Mehran Khodadoust, Ajay Sharma, Reimar Bruening
-
Publication number: 20070105789Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells. The reagent and pharmaceutical formulation of the invention relates to Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.Type: ApplicationFiled: May 24, 2006Publication date: May 10, 2007Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma, Reimar Bruening
-
Publication number: 20070105790Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+e/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers. The subject Na+/K+-ATPase inhibitors, such as cardiac glycosides, including bufadieneolides or their corresponding aglycones (e.g., proscillaridin, scillaren, and scillarenin, etc.), especially in oral formulations and/or solid dosage forms containing more than 1 mg of active ingredients.Type: ApplicationFiled: May 24, 2006Publication date: May 10, 2007Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma, Reimar Bruening
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20070048771Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: July 21, 2006Publication date: March 1, 2007Inventors: Sean McCarthy, Christopher Fraser, John Sharp, Thomas Barnes, Susan Kirst, Paul Myers, Nicholas Wrighton, Andrew Goodearl, Douglas Holtzman, Mehran Khodadoust -
Publication number: 20060276440Abstract: Methods of treating an inflammatory disorder include administering an effective amount of a compound represented by Structural Formula (I): Ring A is optionally substituted, contains zero, one, two, or three double bonds, and is optionally fused to an aliphatic, aryl or heteroaryl ring; X is an optionally substituted 1 to 3 carbon aliphatic chain that is optionally fused to a monocyclic, optionally substituted, aliphatic, heterocyclic, aryl, or heteroaryl ring, wherein one or two carbons in X are optionally replaced with —O—, —S—, or —NRe—; Y is carbon or nitrogen; R1 and R2 are independently —H, —OH, —CN, —NO2, —NRfRg, halogen, optionally substituted alkyl, or optionally substituted alkoxy; or R1 and R2 together link the carbons to which they are bonded with a bond, —O—, —S—, or —NRh—; R3 and R4 are independently —H, —OH, —CN, —NO2, —NRiRj, halogen, optionally substituted alkyl, or optionally substituted alkoxy, or R4 is ?O; or R3 and R4, taken together with the atoms to which they are bonded, form aType: ApplicationFiled: January 3, 2006Publication date: December 7, 2006Inventors: Wenqian An, Jun Park, Mehran Khodadoust, Hans-Jurgen Hess, Md. Hussom
-
Publication number: 20060135468Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to treat refractory cancers using Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain or proscillaridin, etc.).Type: ApplicationFiled: September 1, 2005Publication date: June 22, 2006Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma
-
Publication number: 20060135442Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating pancreatic cancers. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents (chemo- or radio-therapies, etc.) for treating pancreatic cancers.Type: ApplicationFiled: September 2, 2005Publication date: June 22, 2006Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma
-
Publication number: 20060135443Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach for treating hypoxia-related pathological conditions, such as Alzheimer's Disease, and those involving excessive angiogenesis, especially those non-cancer pathological conditions. The invention provides the use of Na+/K+-ATPase inhibitors, such as cardiac glycosides (e.g. ouabain and proscillaridin, etc.), either alone or in combination with other standard therapeutic agents for treating such conditions. The invention also relates to the use of cardiac glycoside inhibitors/antagonists as reagents, pharmaceutical formulations, or in kits and methods for treating conditions arising from excessive amount of cardiac glycosides, including all symptoms of digitalis poisoning, depression, hypertension, etc. The pharmaceutical formulation of the invention may be delivered to a patient either systemically or locally, or both.Type: ApplicationFiled: October 18, 2005Publication date: June 22, 2006Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma
-
Publication number: 20060135441Abstract: The reagent, pharmaceutical formulation, kit, and methods of the invention provides a new approach to alleviate or eliminate certain negative effects associated with the use of certain cancer treatment agents (e.g. chemotherapy therapeutics, etc.) or regimens (e.g. radio therapies, etc.), including stimulation of the hypoxic stress response in tumor cells.Type: ApplicationFiled: September 2, 2005Publication date: June 22, 2006Applicant: Bionaut Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Ajay Sharma
-
Publication number: 20050250709Abstract: In certain aspects, the invention relates to the discovery of novel compositions for use in the treatment of a neoplastic disorder. Further aspects of the invention relate to the discovery that cell signaling may be exploited to identify significant genes in cancer cell lines and to generate reporter gene systems that may be used, for example, to identify anti-neoplastic agents and effective combinations thereof.Type: ApplicationFiled: December 20, 2004Publication date: November 10, 2005Applicant: Bionaut PharmaceuticalsInventor: Mehran Khodadoust
-
Publication number: 20030232378Abstract: The invention provides isolated nucleic acid molecules, designated TOLL nucleic acid molecules, which encode novel TOLL family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TOLL nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TOLL gene has been introduced or disrupted. The invention still further provides isolated TOLL proteins, fusion proteins, antigenic peptides and anti-TOLL antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 13, 2003Publication date: December 18, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventor: Mehran Khodadoust
-
Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
Publication number: 20030170621Abstract: The invention provides isolated nucleic acids encoding a variety of proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods using compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: ApplicationFiled: January 19, 2001Publication date: September 11, 2003Inventors: Sean A. McCarthy, Christopher C. Fraser, John D. Sharp, Thomas M. Barnes, Susan J. Kirst, Paul S. Myers, Nicholas Wrighton, Andrew D.J. Goodearl, Douglas A. Holtzman, Mehran Khodadoust -
Publication number: 20030165975Abstract: The invention provides isolated nucleic acids encoding human lipase proteins and fragments, derivatives, and variants thereof. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders associated, for example, with aberrant lipid metabolism or aberrant pancreatic activity. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides, and antibodies. Diagnostic, prognostic, screening, and therapeutic methods involving use of compositions of the invention are also provided.Type: ApplicationFiled: March 31, 2003Publication date: September 4, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Rosana Kapeller-Libermann
-
Patent number: 6558936Abstract: The invention provides isolated nucleic acids encoding human lipase proteins and fragments, derivatives, and variants thereof. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders associated, for example, with aberrant lipid metabolism or aberrant pancreatic activity. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides, and antibodies. Diagnostic, prognostic, screening, and therapeutic methods involving use of compositions of the invention are also provided.Type: GrantFiled: October 1, 1999Date of Patent: May 6, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Mehran Khodadoust, Rosana Kapeller-Libermann
-
Patent number: 6380382Abstract: The invention provides isolated nucleic acids encoding a variety of nucleic acids and proteins having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: GrantFiled: June 30, 1999Date of Patent: April 30, 2002Assignee: Millennium Pharmaceuticals, Inc.Inventor: Mehran Khodadoust
-
Publication number: 20020004193Abstract: Novel MP-7 polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length MP-7 proteins, the invention further provides isolated MP-7 fusion proteins, antigenic peptides and anti-MP-7 antibodies. The invention also provides MP-7 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a MP-7 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: December 7, 2000Publication date: January 10, 2002Applicant: Millennium Pharmaceuticals, Inc.Inventor: Mehran Khodadoust
-
Patent number: 6291193Abstract: The present invention provides methods for identifying compounds that bind to MTBX, a novel cardiovascular system associated transcription factor regulatory polpeptide.Type: GrantFiled: February 28, 2000Date of Patent: September 18, 2001Assignee: Millennium Pharmaceuticals, Inc.Inventor: Mehran Khodadoust